Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline has announced that the FDA has approved Kinrix, the first combination vaccine to offer protection against diphtheria, tetanus, pertussis and polio diseases in one shot.
Subscribe to our email newsletter
Kinrix (diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine], manufactured by GlaxoSmithKline, is said to be the latest combination vaccine. Clinical studies of Kinrix have demonstrated that this new combination vaccine offers similar protection to the separately administered diphtheria and tetanus toxoids and acellular pertussis (DTaP) and inactivated poliovirus (IPV) vaccines, with a comparable safety profile.
Kinrix is approved for children four to six years of age whose previous diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccinations have been with Pediarix or Infanrix.
Wayde Weston, director, US clinical research and development and medical affairs, GlaxoSmithKline, said: “Kinrix contains the same DTaP and IPV components used in Infanrix and Pediarix, two vaccines which have been used by doctors in the US for many years. With the introduction of Kinrix, eligible four to six year-olds can receive protection against four serious diseases with one less shot.”